Fate Therapeutics, Inc. (FATE)
Market Cap | 366.54M |
Revenue (ttm) | 6.48M |
Net Income (ttm) | -190.05M |
Shares Out | 113.83M |
EPS (ttm) | -1.92 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,111,497 |
Open | 3.230 |
Previous Close | 3.260 |
Day's Range | 3.090 - 3.245 |
52-Week Range | 1.630 - 8.830 |
Beta | 1.90 |
Analysts | Buy |
Price Target | 6.85 (+112.73%) |
Earnings Date | Aug 6, 2024 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. ... [Read more]
Financial Performance
In 2023, FATE's revenue was $63.53 million, a decrease of -34.03% compared to the previous year's $96.30 million. Losses were -$160.93 million, -42.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is $6.85, which is an increase of 112.73% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/4/7/press5-2507423.jpg)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...
![](https://cdn.snapi.dev/images/v1/k/d/press2-2477499.jpg)
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently...
![](https://cdn.snapi.dev/images/v1/x/8/press1-2462427.jpg)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...
![](https://cdn.snapi.dev/images/v1/s/l/conf18-2452472.jpg)
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-c...
![](https://cdn.snapi.dev/images/v1/d/3/press11-2422473.jpg)
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease
![](https://cdn.snapi.dev/images/v1/3/h/press12-2420765.jpg)
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819
![](https://cdn.snapi.dev/images/v1/i/t/press6-2410141.jpg)
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells
![](https://cdn.snapi.dev/images/v1/c/s/press9-2384205.jpg)
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refra...
![](https://cdn.snapi.dev/images/v1/u/v/press15-2353027.jpg)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
![](https://cdn.snapi.dev/images/v1/3/i/press7-2330889.jpg)
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...
![](https://cdn.snapi.dev/images/v1/c/h/conf2-2303394.jpg)
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...
![](https://cdn.snapi.dev/images/v1/n/4/press15-2294412.jpg)
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites
![](https://cdn.snapi.dev/images/v1/i/m/conf5-2277834.jpg)
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...
![](https://cdn.snapi.dev/images/v1/h/y/press4-2195454.jpg)
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...
![](https://cdn.snapi.dev/images/v1/q/k/press3-2147957.jpg)
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning ...
![](https://cdn.snapi.dev/images/v1/v/v/conf14-2119494.jpg)
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...
![](https://cdn.snapi.dev/images/v1/f/g/conf6-2044601.jpg)
Fate Therapeutics to Present at Upcoming September Investor Conferences
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...
![](https://cdn.snapi.dev/images/v1/q/t/press4-2012914.jpg)
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Ch...
![](https://cdn.snapi.dev/images/v1/c/x/conf12-1994338.jpg)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...
![](https://cdn.snapi.dev/images/v1/q/q/press1-1943467.jpg)
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) ...
![](https://cdn.snapi.dev/images/v1/9/g/press6-1927548.jpg)
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on be...
![](https://cdn.snapi.dev/images/v1/g/k/conf15-1913981.jpg)
Fate Therapeutics to Present at Upcoming June Investor Conferences
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-c...
![](https://cdn.snapi.dev/images/v1/s/7/press6-1869465.jpg)
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large ...
![](https://cdn.snapi.dev/images/v1/6/i/conf15-1849696.jpg)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...
![](https://cdn.snapi.dev/images/v1/3/m/press16-1808166.jpg)
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2...